Search
ilunocitinib (Zenrelia)
Indications:
- control of pruritus in dogs at least 12 months of age associated with
- allergic dermatitis
- control of atopic dermatitis
Dosage:
- withhold ilunocitinib for at least 28 days to 3 months before vaccination & for at least 28 days afterward
- verigy a dog is up-to-date on vaccinations before starting treatment
- tablets: 4.8 mg, 6.4 mg, 8.5 mg, 15 mg
Adverse effects:
* Box warninga
- dogs should not be vaccinated <= 28 days before & after Zenrelia treatment
- risk of fatal vaccine-induced disease
- vaccine-induced adenoviral hepatitis & pancreatitis
- infectious enteritis
- inadequate immune response to vaccines
Mechanism of action:
- JAK inhibitor, immunouppressant
Interactions
drug adverse effects of tyrosine kinase inhibitor(s)
General
Janus kinase inhibitor; JAK inhibitor
Database Correlations
PUBCHEM cid=44231134
References
- FDA. 9/19/2024
FDA Approves New Treatment for Allergic Skin Conditions in Dogs
https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-new-treatment-allergic-skin-conditions-dogs
- FDA. 9/19/2024
Dear Veterinarian Letter regarding important safety information associated with
the use of Zenrelia (ilunocitinib tablets) for controlling pruritus associated
with allergic dermatitis and atopic dermatitis in dogs.
https://www.fda.gov/animal-veterinary/product-safety-information/dear-veterinarian-letter-regarding-important-safety-information-associated-use-zenrelia-ilunocitinib
- Elanco: Zenrelia (ilunocitinib tablets)
https://my.elanco.com/us/zenrelia